Trial Profile
A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Pembrolizumab (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Carcinoma; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROPEL
- Sponsors Nektar Therapeutics
- 07 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 03 Sep 2022 This trial has been discontinued in Spain (End Date: 5 July 2022) according to European Clinical Trials Database record.
- 28 Jul 2022 This trial has been discontinued in Italy (End Date: 5 July 2022) according to European Clinical Trials Database record.